Diffuse large B-cell lymphoma

• Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients … Recruitment ended
  2022-500237-92-00 5 2021-04-23 "Newly-diagnosed high-intermediate and high-risk diffuse larg"
• A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refracto … Recruitment ended
  2023-503916-33-00 5 2021-03-24 "Diffuse Large B-Cell Lymphoma (DLBCL)"
• Prephase treatment with prednisone +/- Vitamin D supplementation followed by immunochemotherapy in Elderly patients with Diffuse Large B-Cel … Recruitment ended
  2024-511637-35-00 5 2021-03-23 "Elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL)"
• A Combination of Acalabrutinib with R-CHOP in Subjects with previously untreated non-GCB DLBCL Recruitment ended
  2023-509358-72-00 5 2020-11-23
• Study of Rapcabtagene autoleucel (YTB323) in adult patients with CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL Recruitment ended
  2023-507062-34-00 7 2020-08-07 "High-Risk large B-Cell lymphoma"
• A study to look at how safe and effective glofitamab plus R-CHOP in ctDNA high-risk people with untreated diffuse large B-cell lymphoma Recruitment ended
  2023-504994-19-00 4 2020-06-12 "Diffuse Large B-Cell Lymphoma"
• A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previo … Recruitment ended
  2024-511747-25-00 4 2019-12-23 "B-cell non-Hodgkin lymphoma (NHL)"
• Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutini … Recruitment ended
  2024-511641-18-00 4 2019-08-01 "Diffuse Large B-cell Lymphoma ABC"
• HOVON 151 DLBCL: A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diff … Recruitment ended
  2022-501076-26-00 4 2018-08-28 "high risk diffuse large B-cell lymphoma"
• MB-CART19.1 r/r CD19+ BCM Recruitment ended
  2024-513334-38-00 1 2018-05-15 "Refractory/relapsed B-NHL"
• Transplant BRaVE NHL: Phase I-II study combining Brentuximab Vedotin with second line salvage chemotherapy (R-DHAP) in CD30 positive diffuse … Recruitment ended
  2023-510556-22-00 4 2018-03-05 "non-Hodgkin lymphoma (NHL)"
• Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib Recruitment ended
  2023-507329-40-00 6 2017-09-28 "1. Follicular Lymphoma 2. Chronic Lymphocytic Leukemia 3. Wa"
• A Trial to Study if REGN5837 in Combination with Odronextamab is Safe for Adult Participants with Aggressive B-cell Non-Hodgkin Lymphomas Halted
  2022-502137-26-00 1 2024-05-03 "B-cell Non-Hodgkins Lymphoma (B-NHL)"
• A safety study of PF-08046044/SGN-35C in adults with advanced cancers Ended
  2023-505813-26-00 1 2024-09-12 "Lymphoma, Large B-Cell, Diffuse"
• A safety study of PF-08046045/SGN-35T in adults with advanced cancers Ended
  2022-502390-41-00 1 2024-06-20 "Enteropathy-Associated T-Cell Lymphoma"
• CC-122 Rollover Study Ended
  2022-501855-97-00 3 2023-06-29 "Multiple Myeloma, Follicular Lymphoma, Diffuse Large B-Cell "
• A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients wi … Ended
  2022-501601-12-00 4 2023-05-22 "Diffuse large B-cell Lymphoma"
• INCA 32459-101: A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies Ended
  2022-501505-13-00 1 2023-03-31 "Metastatic melanoma"
• A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cy … Ended
  2023-507497-40-00 1 2021-05-31 "Diffuse large B-cell lymphoma (DLBCL), Grade 3B follicular l"
• A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with pre … Ended
  2024-517166-42-00 4 2020-05-29 "Diffuse large B-cell lymphoma (DLBCL)"
• Tisagenlecleucel in adult patients with aggressive B-cell non-Hodgkin lymphoma Ended
  2023-508343-48-00 5 2019-01-25 "Adult patients with relapsed or refractory aggressive B-cell"
• A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP ( … Ended
  2024-516904-40-00 5 2018-03-27 "Previously Untreated Diffuse large B-cell lymphoma (DLBCL)"
• Study of the safety, activity, and effect on the body of ASTX660 in people with advanced cancers. Ended
  2024-516679-33-00 7 2017-12-01 "Advanced Solid Tumors and Lymphomas that are metastatic or u"

Showing 25–47 of 47 trials